These tumours also express tumour‐associated genetic markers (e.g., CD44v6, CDX2, BRAF) and immune markers (e.g., CD68, CD163), alongside characteristics like CpG island methylator phenotype and KRAS mutations [50]. This evidence concerns the gene KRAS and neoplasm.